Cardiovascular biomarkers: The state of the art in 2006

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: The explosion in cardiovascular biomarkers has been stimulated in large part by proteomics, genomics and an improved understanding of the pathophysiology of cardiovascular disease. New advances are occurring rapidly and remaining on the cutting edge of the science is harder and harder. In the past few years, major changes have evolved in our ability to use cardiac troponin, BNP and CRP which will markedly impact on their clinical utility. These changes including greater sensitivity, a better understanding of what specific fragments are being measured and how these markers are used clinically is obligatory. There is also a need for new markers. Conclusions: As with other disciplines, this work has built on the work of others.

Original languageEnglish (US)
Pages (from-to)9-13
Number of pages5
JournalClinica Chimica Acta
Volume381
Issue number1
DOIs
StatePublished - May 2 2007

Fingerprint

Troponin
Explosions
Biomarkers
Genomics
Proteomics
Cardiovascular Diseases

Keywords

  • Acute coronary syndromes
  • C-reactive protein
  • Cardiovascular biomarkers
  • Natriuretic peptides
  • Troponin

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry

Cite this

Cardiovascular biomarkers : The state of the art in 2006. / Jaffe, Allan S.

In: Clinica Chimica Acta, Vol. 381, No. 1, 02.05.2007, p. 9-13.

Research output: Contribution to journalArticle

@article{f3b66cc257b84f1baf5ed14635163399,
title = "Cardiovascular biomarkers: The state of the art in 2006",
abstract = "Background: The explosion in cardiovascular biomarkers has been stimulated in large part by proteomics, genomics and an improved understanding of the pathophysiology of cardiovascular disease. New advances are occurring rapidly and remaining on the cutting edge of the science is harder and harder. In the past few years, major changes have evolved in our ability to use cardiac troponin, BNP and CRP which will markedly impact on their clinical utility. These changes including greater sensitivity, a better understanding of what specific fragments are being measured and how these markers are used clinically is obligatory. There is also a need for new markers. Conclusions: As with other disciplines, this work has built on the work of others.",
keywords = "Acute coronary syndromes, C-reactive protein, Cardiovascular biomarkers, Natriuretic peptides, Troponin",
author = "Jaffe, {Allan S}",
year = "2007",
month = "5",
day = "2",
doi = "10.1016/j.cca.2007.02.029",
language = "English (US)",
volume = "381",
pages = "9--13",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Cardiovascular biomarkers

T2 - The state of the art in 2006

AU - Jaffe, Allan S

PY - 2007/5/2

Y1 - 2007/5/2

N2 - Background: The explosion in cardiovascular biomarkers has been stimulated in large part by proteomics, genomics and an improved understanding of the pathophysiology of cardiovascular disease. New advances are occurring rapidly and remaining on the cutting edge of the science is harder and harder. In the past few years, major changes have evolved in our ability to use cardiac troponin, BNP and CRP which will markedly impact on their clinical utility. These changes including greater sensitivity, a better understanding of what specific fragments are being measured and how these markers are used clinically is obligatory. There is also a need for new markers. Conclusions: As with other disciplines, this work has built on the work of others.

AB - Background: The explosion in cardiovascular biomarkers has been stimulated in large part by proteomics, genomics and an improved understanding of the pathophysiology of cardiovascular disease. New advances are occurring rapidly and remaining on the cutting edge of the science is harder and harder. In the past few years, major changes have evolved in our ability to use cardiac troponin, BNP and CRP which will markedly impact on their clinical utility. These changes including greater sensitivity, a better understanding of what specific fragments are being measured and how these markers are used clinically is obligatory. There is also a need for new markers. Conclusions: As with other disciplines, this work has built on the work of others.

KW - Acute coronary syndromes

KW - C-reactive protein

KW - Cardiovascular biomarkers

KW - Natriuretic peptides

KW - Troponin

UR - http://www.scopus.com/inward/record.url?scp=34248209728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248209728&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2007.02.029

DO - 10.1016/j.cca.2007.02.029

M3 - Article

C2 - 17368598

AN - SCOPUS:34248209728

VL - 381

SP - 9

EP - 13

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 1

ER -